|
Description
Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, has reported on its corporate progress and financial results for the quarter ended June 30, 2007.
"Poniard achieved significant milestones during the last quarter, including the initiation of our pivotal Phase 3 SPEAR trial of picoplatin in small cell lung cancer, presentation at ASCO of results from our Phase 2 trial in small cell lung cancer and our Phase 1 combination trials in first-line colorectal and hormone refractory prostate cancers, and completion of a $75 million financing," said Jerry McMahon, Ph.D., chairman and CEO of Poniard. "We continue to advance our picoplatin clinical development programs and recently began enrollment in our Phase 2 trial in metastatic hormone-refractory prostate cancer. We expect to start the Phase 2 component of our trial in metastatic colorectal cancer later this year."
Second Quarter and Recent Highlights
Picoplatin and... |
Looking for additional articles?
Click here
to search our database of over 3 million articles.
|
%20%20&position=1)